MacroGenics Other Assets vs Net Debt Analysis

MGNX Stock

USD 4.37 0.75 14.65%

MacroGenics financial indicator trend analysis is infinitely more than just investigating MacroGenics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether MacroGenics is a good investment. Please check the relationship between MacroGenics Other Assets and its Net Debt accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MacroGenics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy MacroGenics Stock please use our How to Invest in MacroGenics guide.

Other Assets vs Net Debt

Other Assets vs Net Debt Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of MacroGenics Other Assets account and Net Debt. At this time, the significance of the direction appears to have no relationship.

The correlation between MacroGenics' Other Assets and Net Debt is 0.04. Overlapping area represents the amount of variation of Other Assets that can explain the historical movement of Net Debt in the same time period over historical financial statements of MacroGenics, assuming nothing else is changed. The correlation between historical values of MacroGenics' Other Assets and Net Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Assets of MacroGenics are associated (or correlated) with its Net Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Debt has no effect on the direction of Other Assets i.e., MacroGenics' Other Assets and Net Debt go up and down completely randomly.

Correlation Coefficient

0.04

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Other Assets

Net Debt

The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.

Most indicators from MacroGenics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into MacroGenics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MacroGenics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy MacroGenics Stock please use our How to Invest in MacroGenics guide.Selling General Administrative is likely to drop to about 37 M in 2024. Issuance Of Capital Stock is likely to drop to about 585.2 K in 2024

	2021	2022	2023	2024 (projected)
Total Operating Expenses	275.8M	266.0M	209.1M	180.3M
Cost Of Revenue	2.7M	7.4M	17.9M	17.0M

Total Operating Expenses Cost Of Revenue

MacroGenics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Common Stock
Total Assets		0.31	0.38	0.97	-0.24	0.78	-0.33	-0.58	-0.53	-0.13	0.74	0.8	0.41	0.22	0.95	0.39	0.81	0.74	0.08	0.64	0.76	0.21	0.52	0.99	-0.28	0.84
Other Current Liab	0.31		0.3	0.24	0.13	0.31	-0.02	0.0	-0.26	0.2	0.08	0.32	0.14	0.09	0.26	0.18	0.15	0.49	0.21	0.26	0.29	0.3	0.25	0.29	-1.0	0.15
Total Current Liabilities	0.38	0.3		0.2	0.01	0.67	0.24	-0.02	-0.67	0.64	0.17	0.67	0.38	0.61	0.16	0.45	0.54	0.67	0.29	0.71	0.66	0.7	0.68	0.27	-0.28	0.54
Total Stockholder Equity	0.97	0.24	0.2		-0.39	0.62	-0.5	-0.66	-0.33	-0.22	0.78	0.68	0.43	0.19	0.98	0.23	0.68	0.56	-0.12	0.52	0.59	-0.04	0.37	0.98	-0.21	0.71
Other Liab	-0.24	0.13	0.01	-0.39		0.1	0.64	0.36	-0.33	-0.14	-0.23	-0.12	-0.73	-0.46	-0.31	0.37	-0.02	0.09	0.84	-0.3	0.06	0.56	0.24	-0.25	-0.16	-0.05
Property Plant And Equipment Net	0.78	0.31	0.67	0.62	0.1		0.15	-0.35	-0.72	-0.04	0.54	0.95	0.31	0.14	0.56	0.75	0.82	0.84	0.41	0.65	0.84	0.65	0.58	0.68	-0.29	0.83
Current Deferred Revenue	-0.33	-0.02	0.24	-0.5	0.64	0.15		0.45	-0.36	0.23	-0.38	0.01	-0.46	-0.02	-0.54	0.67	0.04	0.18	0.58	0.02	0.18	0.62	-0.05	-0.39	-0.01	0.04
Net Debt	-0.58	0.0	-0.02	-0.66	0.36	-0.35	0.45		-0.2	0.43	-0.93	-0.31	-0.18	0.04	-0.63	-0.12	-0.22	-0.05	0.42	-0.05	-0.08	0.27	0.06	-0.61	-0.02	-0.25
Retained Earnings	-0.53	-0.26	-0.67	-0.33	-0.33	-0.72	-0.36	-0.2		-0.3	-0.12	-0.72	-0.22	-0.34	-0.31	-0.62	-0.83	-0.89	-0.75	-0.78	-0.91	-0.81	-0.82	-0.44	0.26	-0.83
Accounts Payable	-0.13	0.2	0.64	-0.22	-0.14	-0.04	0.23	0.43	-0.3		-0.38	0.06	0.31	0.69	-0.22	-0.04	0.02	0.22	0.04	0.44	0.2	0.33	0.28	-0.17	-0.2	0.02
Cash	0.74	0.08	0.17	0.78	-0.23	0.54	-0.38	-0.93	-0.12	-0.38		0.51	0.26	0.0	0.74	0.27	0.45	0.29	-0.14	0.27	0.32	-0.08	0.23	0.76	-0.05	0.48
Non Current Assets Total	0.8	0.32	0.67	0.68	-0.12	0.95	0.01	-0.31	-0.72	0.06	0.51		0.56	0.25	0.59	0.66	0.83	0.85	0.28	0.79	0.85	0.54	0.57	0.7	-0.3	0.85
Non Currrent Assets Other	0.41	0.14	0.38	0.43	-0.73	0.31	-0.46	-0.18	-0.22	0.31	0.26	0.56		0.43	0.32	-0.05	0.35	0.35	-0.31	0.68	0.36	-0.04	0.22	0.34	-0.12	0.38
Other Assets	0.22	0.09	0.61	0.19	-0.46	0.14	-0.02	0.04	-0.34	0.69	0.0	0.25	0.43		0.16	-0.02	0.33	0.38	-0.21	0.67	0.4	0.14	0.38	0.2	-0.08	0.35
Cash And Short Term Investments	0.95	0.26	0.16	0.98	-0.31	0.56	-0.54	-0.63	-0.31	-0.22	0.74	0.59	0.32	0.16		0.13	0.66	0.54	-0.07	0.45	0.56	-0.03	0.42	0.98	-0.23	0.68
Net Receivables	0.39	0.18	0.45	0.23	0.37	0.75	0.67	-0.12	-0.62	-0.04	0.27	0.66	-0.05	-0.02	0.13		0.55	0.62	0.52	0.44	0.63	0.66	0.2	0.3	-0.19	0.58
Common Stock Total Equity	0.81	0.15	0.54	0.68	-0.02	0.82	0.04	-0.22	-0.83	0.02	0.45	0.83	0.35	0.33	0.66	0.55		0.91	0.4	0.81	0.96	0.59	0.67	0.76	-0.13	0.99
Common Stock Shares Outstanding	0.74	0.49	0.67	0.56	0.09	0.84	0.18	-0.05	-0.89	0.22	0.29	0.85	0.35	0.38	0.54	0.62	0.91		0.51	0.85	0.97	0.73	0.69	0.66	-0.48	0.91
Non Current Liabilities Total	0.08	0.21	0.29	-0.12	0.84	0.41	0.58	0.42	-0.75	0.04	-0.14	0.28	-0.31	-0.21	-0.07	0.52	0.4	0.51		0.2	0.49	0.78	0.59	0.03	-0.23	0.38
Other Current Assets	0.64	0.26	0.71	0.52	-0.3	0.65	0.02	-0.05	-0.78	0.44	0.27	0.79	0.68	0.67	0.45	0.44	0.81	0.85	0.2		0.87	0.49	0.62	0.56	-0.24	0.83
Other Stockholder Equity	0.76	0.29	0.66	0.59	0.06	0.84	0.18	-0.08	-0.91	0.2	0.32	0.85	0.36	0.4	0.56	0.63	0.96	0.97	0.49	0.87		0.72	0.7	0.69	-0.28	0.96
Total Liab	0.21	0.3	0.7	-0.04	0.56	0.65	0.62	0.27	-0.81	0.33	-0.08	0.54	-0.04	0.14	-0.03	0.66	0.59	0.73	0.78	0.49	0.72		0.59	0.11	-0.3	0.56
Property Plant And Equipment Gross	0.52	0.25	0.68	0.37	0.24	0.58	-0.05	0.06	-0.82	0.28	0.23	0.57	0.22	0.38	0.42	0.2	0.67	0.69	0.59	0.62	0.7	0.59		0.47	-0.23	0.66
Total Current Assets	0.99	0.29	0.27	0.98	-0.25	0.68	-0.39	-0.61	-0.44	-0.17	0.76	0.7	0.34	0.2	0.98	0.3	0.76	0.66	0.03	0.56	0.69	0.11	0.47		-0.26	0.78
Short Term Debt	-0.28	-1.0	-0.28	-0.21	-0.16	-0.29	-0.01	-0.02	0.26	-0.2	-0.05	-0.3	-0.12	-0.08	-0.23	-0.19	-0.13	-0.48	-0.23	-0.24	-0.28	-0.3	-0.23	-0.26		-0.13
Common Stock	0.84	0.15	0.54	0.71	-0.05	0.83	0.04	-0.25	-0.83	0.02	0.48	0.85	0.38	0.35	0.68	0.58	0.99	0.91	0.38	0.83	0.96	0.56	0.66	0.78	-0.13

Click cells to compare fundamentals

MacroGenics Account Relationship Matchups

MacroGenics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	312.5M	378.7M	335.2M	280.5M	298.4M	287.5M
Other Current Liab	27.1M	27.3M	33.8M	(30.5M)	24.2M	25.5M
Total Current Liabilities	45.2M	50.7M	74.6M	48.6M	56.1M	47.8M
Total Stockholder Equity	230.6M	295.9M	239.6M	142.0M	152.6M	199.6M
Other Liab	9.2M	6.9M	258K	59.7M	53.8M	56.5M
Property Plant And Equipment Net	48.2M	42.2M	37.7M	56.9M	45.7M	32.9M
Current Deferred Revenue	10.7M	11.4M	20.6M	69.5M	21.7M	22.3M
Net Debt	(95.9M)	(151.9M)	(98.0M)	(74.1M)	(67.0M)	(70.3M)
Retained Earnings	(642.1M)	(771.8M)	(973.9M)	(1.1B)	(1.1B)	(1.0B)
Accounts Payable	4.3M	8.0M	15.5M	4.9M	6.4M	6.1M
Cash	126.5M	181.1M	123.5M	108.9M	101.0M	146.4M
Non Current Assets Total	72.7M	66.1M	55.7M	58.3M	47.1M	40.8M
Non Currrent Assets Other	24.5M	23.9M	18.0M	(7.7M)	1.4M	1.3M
Other Assets	4.3M	23.9M	335.2M	1.4M	1.0	0.95
Cash And Short Term Investments	215.8M	272.5M	243.6M	154.3M	229.8M	224.7M
Net Receivables	12.7M	23.1M	10.4M	56.2M	10.4M	14.4M
Common Stock Total Equity	490K	562K	613K	617K	709.6K	396.0K
Common Stock Shares Outstanding	48.1M	52.4M	59.9M	61.4M	61.9M	42.1M
Liabilities And Stockholders Equity	312.5M	378.7M	335.2M	280.5M	298.4M	287.5M
Non Current Liabilities Total	36.7M	32.2M	21.0M	89.8M	89.7M	94.2M
Other Current Assets	11.3M	17.0M	21.2M	10.2M	9.9M	7.7M
Other Stockholder Equity	872.2M	1.1B	1.2B	1.2B	1.3B	774.0M
Total Liab	81.9M	82.9M	95.6M	138.5M	145.8M	87.9M
Property Plant And Equipment Gross	48.2M	42.2M	110.5M	29.6M	134.1M	140.8M
Total Current Assets	239.8M	312.6M	279.6M	222.2M	251.3M	246.7M
Accumulated Other Comprehensive Income	(61K)	(3K)	16K	(7K)	(6K)	(6.3K)
Short Term Debt	3.0M	4.0M	4.7M	4.7M	3.8M	3.6M
Common Stock	490K	562K	613K	617K	621K	418.1K
Property Plant Equipment	68.4M	42.2M	37.7M	29.6M	34.0M	30.8M
Net Tangible Assets	230.6M	295.9M	239.6M	142.0M	163.3M	245.6M
Short Term Investments	89.3M	91.4M	120.1M	45.5M	128.8M	91.7M
Capital Surpluse	872.2M	1.1B	1.2B	1.2B	1.4B	817.2M
Deferred Long Term Liab	24.9M	29.3M	6.9M	59.5M	68.4M	71.8M
Net Invested Capital	230.6M	295.9M	239.6M	142.0M	152.6M	183.2M
Net Working Capital	194.6M	261.9M	205.0M	173.6M	195.2M	172.8M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
CRM	Salesforce
MSFT	Microsoft

When determining whether MacroGenics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of MacroGenics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Macrogenics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Macrogenics Stock:

How To Invest In MacroGenics

Details

Is MacroGenics Stock a good investment?

Details

What is MacroGenics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MacroGenics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.

For more information on how to buy MacroGenics Stock please use our How to Invest in MacroGenics guide.

You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for MacroGenics Stock analysis

When running MacroGenics' price analysis, check to measure MacroGenics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MacroGenics is operating at the current time. Most of MacroGenics' value examination focuses on studying past and present price action to predict the probability of MacroGenics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MacroGenics' price. Additionally, you may evaluate how the addition of MacroGenics to your portfolios can decrease your overall portfolio volatility.

	Money Managers Screen money managers from public funds and ETFs managed around the world
	Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
	Bonds Directory Find actively traded corporate debentures issued by US companies
	Volatility Analysis Get historical volatility and risk analysis based on latest market data
	Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments

Is MacroGenics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of MacroGenics. If investors know MacroGenics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about MacroGenics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.38)

Revenue Per Share

0.699

Quarterly Revenue Growth

(0.63)

Return On Assets

(0.39)

Return On Equity

(0.22)

The market value of MacroGenics is measured differently than its book value, which is the value of MacroGenics that is recorded on the company's balance sheet. Investors also form their own opinion of MacroGenics' value that differs from its market value or its book value, called intrinsic value, which is MacroGenics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because MacroGenics' market value can be influenced by many factors that don't directly affect MacroGenics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between MacroGenics' value and its price as these two are different measures arrived at by different means. Investors typically determine if MacroGenics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, MacroGenics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

MacroGenics Other Assets vs Net Debt Analysis

Other Assets vs Net Debt

Other Assets vs Net Debt Correlation Analysis

Correlation Coefficient

Other Assets

Net Debt

MacroGenics fundamental ratios Correlations

MacroGenics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

MacroGenics fundamental ratios Accounts

Also Currently Popular

Complementary Tools for MacroGenics Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 0.99	Total Assets
Common Stock	+ 0.99	Common Stock Total Equity
Cash And Short Term Investments	+ 0.98	Total Stockholder Equity
Total Current Assets	+ 0.98	Total Stockholder Equity
Total Current Assets	+ 0.98	Cash And Short Term Investments
Total Stockholder Equity	+ 0.97	Total Assets

Short Term Debt	- 1.0	Other Current Liab
Cash	- 0.93	Net Debt
Other Stockholder Equity	- 0.91	Retained Earnings
Common Stock Shares Outstanding	- 0.89	Retained Earnings
Common Stock	- 0.83	Retained Earnings
Common Stock Total Equity	- 0.83	Retained Earnings